179 related articles for article (PubMed ID: 35448639)
1. Revisit of the Association between Cytomegalovirus Infection and Invasive Fungal Infection after Allogeneic Hematopoietic Stem Cell Transplantation: A Real-World Analysis from a High CMV Seroprevalence Area.
Yeh TJ; Yang CI; Huang CT; Wang MH; Chuang TM; Ke YL; Gau YC; Du JS; Wang HC; Cho SF; Lee CP; Hsu CM; Hsiao HH; Liu YC
J Fungi (Basel); 2022 Apr; 8(4):. PubMed ID: 35448639
[TBL] [Abstract][Full Text] [Related]
2. The association of cytomegalovirus infection and cytomegalovirus serostatus with invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients: a systematic review and meta-analysis.
Chuleerarux N; Nematollahi S; Thongkam A; Dioverti MV; Manothummetha K; Torvorapanit P; Langsiri N; Worasilchai N; Plongla R; Chindamporn A; Sanguankeo A; Permpalung N
Clin Microbiol Infect; 2022 Mar; 28(3):332-344. PubMed ID: 34752926
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
[TBL] [Abstract][Full Text] [Related]
5. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
[TBL] [Abstract][Full Text] [Related]
6. A clinical study of lyophilized intravenous human immunoglobulin containing high-titer cytomegalovirus-neutralizing antibody for the treatment of cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation.
Zhang P; Yang D; Tian J; Feng S; Jiang E; Han M
Ann Palliat Med; 2021 May; 10(5):5533-5540. PubMed ID: 34107701
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus Infection and Treatment in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study from a Single Institution in an Endemic Area.
Lin HC; Han SM; Hwang WL; Chou CW; Chang KH; Shi ZY; Jerry Teng CL
Turk J Haematol; 2017 Jun; 34(2):159-166. PubMed ID: 27610628
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus.
Liu YC; Lu PL; Hsiao HH; Chang CS; Liu TC; Yang WC; Lin SF
Ann Hematol; 2012 Apr; 91(4):587-95. PubMed ID: 21997849
[TBL] [Abstract][Full Text] [Related]
9. Negative Impact of Cytomegalovirus Reactivation on Survival in Adult Patients with Aplastic Anemia after an Allogeneic Hematopoietic Stem Cell Transplantation: A Report from Transplantation-Related Complication and Adult Aplastic Anemia Working Groups of the Japan Society for Hematopoietic Cell Transplantation.
Takenaka K; Onishi Y; Mori T; Hirakawa T; Tada Y; Uchida N; Kobayashi T; Kanda Y; Ozawa Y; Ota S; Iida H; Fukushima K; Kimua T; Fukuda T; Atsuta Y; Matsuto K; Yamazaki H; Nakasone H
Transplant Cell Ther; 2021 Jan; 27(1):82.e1-82.e8. PubMed ID: 33039517
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load Monitoring.
Yong MK; Ananda-Rajah M; Cameron PU; Morrissey CO; Spencer A; Ritchie D; Cheng AC; Lewin SR; Slavin M
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1961-1967. PubMed ID: 28797778
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II-IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group.
Kimura SI; Tamaki M; Okinaka K; Seo S; Uchida N; Igarashi A; Ozawa Y; Ikegame K; Eto T; Tanaka M; Shiratori S; Nakamae H; Sawa M; Kawakita T; Onizuka M; Fukuda T; Atsuta Y; Kanda Y; Nakasone H
Ann Hematol; 2021 Dec; 100(12):3029-3038. PubMed ID: 34490500
[TBL] [Abstract][Full Text] [Related]
12. Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality.
Liu J; Kong J; Chang YJ; Chen H; Chen YH; Han W; Wang Y; Yan CH; Wang JZ; Wang FR; Chen Y; Zhang XH; Xu LP; Liu KY; Huang XJ
Clin Microbiol Infect; 2015 Dec; 21(12):1121.e9-15. PubMed ID: 26093077
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review.
Jerry Teng CL; Wang PN; Chen YC; Ko BS
J Microbiol Immunol Infect; 2021 Jun; 54(3):341-348. PubMed ID: 33514495
[TBL] [Abstract][Full Text] [Related]
14. CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality.
Eberhardt KA; Jung V; Knops E; Heger E; Wirtz M; Steger G; Kaiser R; Affeldt P; Holtick U; Klein F; Scheid C; Di Cristanziano V
Bone Marrow Transplant; 2023 Jun; 58(6):639-646. PubMed ID: 36869190
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Cytomegalovirus Reactivation by Recipient Cytomegalovirus-IgG Titer before Allogeneic Hematopoietic Stem Cell Transplantation.
Kawamura S; Nakasone H; Takeshita J; Kimura SI; Nakamura Y; Kawamura M; Yoshino N; Misaki Y; Yoshimura K; Matsumi S; Gomyo A; Akahoshi Y; Kusuda M; Kameda K; Tanihara A; Tamaki M; Kako S; Kanda Y
Transplant Cell Ther; 2021 Aug; 27(8):683.e1-683.e7. PubMed ID: 33984537
[TBL] [Abstract][Full Text] [Related]
16. Association between the kinetics of cytomegalovirus reactivation evaluated in terms of the area under the curve of cytomegalovirus antigenemia and invasive mold infection during the post-engraftment phase after allogeneic hematopoietic stem cell transplantation.
Kimura SI; Takeshita J; Kawamura M; Kawamura S; Yoshino N; Misaki Y; Yoshimura K; Matsumi S; Gomyo A; Akahoshi Y; Tamaki M; Kusuda M; Kameda K; Wada H; Kawamura K; Sato M; Terasako-Saito K; Tanihara A; Nakasone H; Kako S; Kanda Y
Transpl Infect Dis; 2020 Oct; 22(5):e13387. PubMed ID: 32585736
[TBL] [Abstract][Full Text] [Related]
17. [Cytomegalovirus infection monitoring in patients with long-term survival after allogeneic hematopoietic stem cell transplantation].
Chen L; Luo Y; Hu Y; Tan Y; Zhao Y; Fan J; Huang H
Zhonghua Yi Xue Za Zhi; 2014 Nov; 94(40):3145-9. PubMed ID: 25573309
[TBL] [Abstract][Full Text] [Related]
18. [Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation].
Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Zhao XS; Yu L; Han W; Zhang XH; Wang Y; Chen Y; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):77-81. PubMed ID: 19563015
[TBL] [Abstract][Full Text] [Related]
19. Risks and outcomes of invasive fungal infections in pediatric allogeneic hematopoietic stem cell transplant recipients receiving fluconazole prophylaxis: a multicenter cohort study by the Turkish Pediatric Bone Marrow Transplantation Study Group.
Hazar V; Karasu GT; Uygun V; Öztürk G; Kiliç SÇ; Küpesiz A; Daloglu H; Aksoylar S; Atay D; Ince EÜ; Karakükçü M; Özbek N; Tayfun F; Kansoy S; Özyürek E; Akçay A; Gürsel O; Haskologlu S; Kaya Z; Yilmaz S; Tanyeli A; Yesilipek A
Med Mycol; 2019 Feb; 57(2):161-170. PubMed ID: 29608706
[TBL] [Abstract][Full Text] [Related]
20. Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.
Dwabe S; Hsiao M; Ali A; Rodman J; Savitala-Damerla L; Nazaretyan S; Kimberly Schiff NP; Tam E; Ladha A; Woan K; Chaudhary P; Yaghmour G
Transpl Immunol; 2023 Feb; 76():101769. PubMed ID: 36464218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
